mRNA shouldn’t have a party affiliation
Top Story
Archived
•
October 27, 2026
•
Cancer medicine had an extraordinary weekend in Madrid. At the European Society for Medical Oncology Congress, Amgen’s Imdelltra, added to AstraZeneca’s Imfinzi as maintenance therapy for extensive-stage small-cell lung cancer, cut the risk of death by 58%. Median survival rose from just under 13 months to a little over 21 months. Then came another landmark […]
Source: Washington Examiner | https://www.washingtonexaminer.com/feed - Read Original
Discussion (0)
Please log in to post a comment.
No comments yet. Be the first to share your thoughts!



